Ikena raises ~$40M in equity offering; Q1 cash $137.8M; runway to 2026

ImageneBio, Inc.

Underwritten offering of 6.11M shares at $6.55/share for gross proceeds of ~$40M; closing expected May 17, 2023.
Cash, equivalents and marketable securities $137.8M at March 31, 2023; offering proceeds extend cash runway into 2026.
Q1 collaboration revenue $5.3M (up from $3.4M YoY); R&D expense $15.6M; G&A $5.3M.
IK-930 initial monotherapy data expected 4Q 2023; IK-595 IND filing planned 2H 2023; IK-175 Fast Track designation in March.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ImageneBio, Inc. entered into Underwriting Agreement with Cowen and Company, LLC and William Blair & Company, L.L.C., as representatives of the underwriters valued at approximately $40,020,500 million (effective 2023-05-15).

Action: entry
Agreement: underwriting
Counterparty: Cowen and Company, LLC and William Blair & Company, L.L.C., as representatives of the underwriters
Value: approximately $40,020,500 million
Effective: 2023-05-15

Exact text from the filing

On May 15, 2023, Ikena Oncology, Inc., a Delaware corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cowen and Company, LLC and William Blair & Company, L.L.C., as representatives of the underwriters listed on Schedule A thereto (collectively, the “Underwriters”), relating to an underwritten registered offering (the “Offering”) of 6,110,000 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), at a price of $6.550 per share, less underwriting discounts and commissions.

View on SEC.gov

114 material agreements filed in the last 30 days. Browse all material agreements →

ImageneBio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-144274

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.